[Pathogenetic treatment of multiple sclerosis: the present and the future] - In this review, we present results of studies of drugs modifying the MS course which have been approved for MS treatment and those that are in the stage of clinical trials and expected to enlarge possibilities of MS treatment. - Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(7 Suppl 2):90-9. in PubMed

[Brain atrophy and neurological impairment in patients with multiple sclerosis] - An aim of the study was to investigate a relationship between global and local brain atrophy with neurological impairment (motor dysfunction) in multiple sclerosis (MS) patients with different levels of disease severity. - Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(7 Suppl 2):32-7. in PubMed

The effect of war stress on multiple sclerosis exacerbations and radiological disease activity. - Our study shows that exposure to war-related events is likely to lead to an increase in both clinical relapses and MRI disease activity in patients with MS. - J Neurol Sci. 2009 Nov 3. [Epub ahead of print] in PubMed

Magnetic resonance imaging characteristics of children and adults with paediatric-onset multiple sclerosis. - The purpose of this study was to compare the clinical and quantitative magnetic resonance imaging metrics of paediatric-onset multiple sclerosis to adult-onset multiple sclerosis. - Brain 2009 Nov 5. [Epub ahead of print] in PubMed

The diagnostic value of earlier and later components of Vestibular Evoked Myogenic Potentials (VEMP) in multiple sclerosis. - Abnormal VEMP imply the presence of lesions undetected by MRI neuroimaging, which verifies the diagnostic value of the method. Unilateral absence of n34p44 complex was related with sensorineural hearing loss, supporting the hypothesis that n34p44 is of cochlear origin. - J Vestib Res. 2009;19(1-2):59-66. in PubMed

Molecular profiling of glatiramer acetate early treatment effects in multiple sclerosis. - Our findings demonstrate that GA treatment induces alternations of immunomodulatory gene expression patterns that are important for suppression of disease activity already at three months of treatment and can be used as molecular markers of GA activity. -Dis Markers 2009;27(2):63-73. in PubMed

The impact of disability, fatigue and sleep quality on the quality of life in multiple sclerosis. - In conclusion, it may be said that MS patients had poor and moderate quality of mental and physical health. The quality of life was impaired as seen by PSQI, EDSS, and FSS. It is our suggestion that these patients require the attention of health care professionals, to be observed for the need of possible psychological support. - Ann Indian Acad Neurol. 2008 Oct;11(4):236-41. in PubMed

Optic neuritis--more than a loss of vision. - Aust Fam Physician 2009 Oct;38(10):789-93. in PubMed

[Multiple sclerosis at the time of world-wide use of disease modifying treatment] - The review discusses issues of multiple sclerosis (MS) management at the time of world-wide use of effective treatment - disease modifying treatment including the influence of the time of treatment start and adherence to treatment on its results, monitoring and treatment strategy of neurodegenerative disorders, problems of new trials, changes in MS course and significance of symptomatic treatment and rehabilitation. The discussion of many aspects is based on the data presented in the articles published in this special issue of the journal. - Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(7 Suppl 2):4-9. in PubMed

[Genetic predisposition to multiple sclerosis as a polygenic autoimmune disease] - The biological properties of the MS-associated genes support the notion that autoimmune inflammatory processes play an important role in MS, whereas an existence of mainly non-overlapping subgroups of patients bearing different predisposing genetic factors is consistent with the MS genetic heterogeneity. - Zh Nevrol Psikhiatr Im S S Korsakova. 2009;109(7 Suppl 2):16-22. in PubMed